Myriad Genetics Stock Analysis

Myriad Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Myriad Genetics has Price/Earnings To Growth (PEG) ratio of 1.4. The entity recorded a loss per share of 1.12. The firm had not issued any dividends in recent years. Myriad Genetics had 2:1 split on the 26th of March 2009. Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2400 people. To find out more about Myriad Genetics contact Paul Diaz at 801 584 3600 or learn more at https://www.myriad.com.

Myriad Genetics Investment Alerts

Myriad Genetics Upcoming and Recent Events

Myriad Largest EPS Surprises

View All Earnings Estimates

Myriad Genetics Environmental, Social, and Governance (ESG) Scores

Myriad Stock Institutional Investors

Note, although Myriad Genetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Myriad Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 412.03 M.

Myriad Profitablity

The company has Profit Margin (PM) of (0.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15.

Management Efficiency

Myriad Genetics has return on total asset (ROA) of (0.0526) % which means that it has lost $0.0526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1384) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of July 2025, Return On Tangible Assets is likely to grow to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.14. At this time, Myriad Genetics' Non Currrent Assets Other are very stable compared to the past year. As of the 19th of July 2025, Other Current Assets is likely to grow to about 55.4 M, while Total Assets are likely to drop about 686.6 M.

Technical Drivers

As of the 19th of July, Myriad Genetics secures the Standard Deviation of 6.57, risk adjusted performance of (0.08), and Mean Deviation of 3.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Myriad Genetics, as well as the relationship between them.

Myriad Genetics Price Movement Analysis

Myriad Genetics Insider Trading Activities

Myriad Genetics Outstanding Bonds

Myriad Genetics Predictive Daily Indicators

Myriad Genetics Forecast Models

Myriad Genetics' time-series forecasting models are one of many Myriad Genetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Myriad Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Myriad Genetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Myriad shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Myriad Genetics. By using and applying Myriad Stock analysis, traders can create a robust methodology for identifying Myriad entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Myriad analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Myriad analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Myriad Genetics stock analysis indicators help investors evaluate how Myriad Genetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Myriad Genetics shares will generate the highest return on investment. By understating and applying Myriad Genetics stock analysis, traders can identify Myriad Genetics position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.